"The U.S. Food and Drug Administration today approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized).
Medullary thyroid cancer develops in cells in the thyroid gland that m"...
Patients should be informed of the following information to aid in the safe and effective use of THYRO-TABS (levothyroxine sodium) Ã?:
1. Notify your physician if you are allergic to any foods or medicines, are pregnant or intend to become pregnant, are breast-feeding or are taking any other medications, including prescription and over-the-counter preparations.
2. Notify your physician of any other medical conditions you may have, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary gland problems. Your dose of medications used to control these other conditions may need to be adjusted while you are taking THYRO-TABS (levothyroxine sodium) Ã?. If you have diabetes, monitor your blood and/or urinary glucose levels as directed by your physician and immediately report any changes to your physician. If you are taking anticoagulants (blood thinners), your clotting status should be checked frequently.
3. Use THYRO-TABS (levothyroxine sodium) Ã? only as prescribed by your physician. Do not discontinue or change the amount you take or how often you take it, unless directed to do so by your physician.
4. The levothyroxine in THYRO-TABS (levothyroxine sodium) Ã? is intended to replace a hormone that is normally produced by your thyroid gland. Generally, replacement therapy is to be taken for life, except in cases of transient hypothyroidism, which is usually associated with an inflammation of the thyroid gland (thyroiditis).
6. It may take several weeks before you notice an improvement in your symptoms.
7. Notify your physician if you experience any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, tremors, change in appetite, weight gain or loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods, hives or skin rash, or any other unusual medical event.
8. Notify your physician if you become pregnant while taking THYRO-TABS (levothyroxine sodium) Ã?. It is likely that your dose of THYRO-TABS (levothyroxine sodium) Ã? will need to be increased while you are pregnant.
9. Notify your physician or dentist that you are taking THYRO-TABS (levothyroxine sodium) Ã? prior to any surgery.
10. Partial hair loss may occur rarely during the first few months of THYRO-TABS (levothyroxine sodium) Ã? therapy, but this is usually temporary.
11. THYRO-TABS (levothyroxine sodium) Ã? should not be used as a primary or adjunctive therapy in a weight control program.
12. Keep THYRO-TABS (levothyroxine sodium) Ã? out of the reach of children. Store THYRO-TABS (levothyroxine sodium) Ã? away from heat, moisture, and light.
13. Agents such as iron and calcium supplements and antacids can decrease the absorption of levothyroxine sodium tablets. Therefore, levothyroxine sodium tablets should not be administered within 4 hrs of these agents.
Last reviewed on RxList: 4/14/2006
This monograph has been modified to include the generic and brand name in many instances.
Additional Thyro-Tabs Information
Report Problems to the Food and Drug Administration
Find out what women really need.